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 Abstract 
 Background/Aims: This study examines the longitudinal effect of metabolic syndrome (MetS) 
on brain-aging indices among cognitively normal (CN) and amnestic mild cognitive impair-
ment (aMCI) groups [single-domain aMCI (saMCI) and multiple-domain aMCI (maMCI)]. 
 Methods: The study population included 739 participants (CN = 226, saMCI = 275, and
maMCI = 238) from the Alzheimer’s Disease Neuroimaging Initiative, a clinic-based, multi-
center prospective cohort. Confirmatory factor analysis was employed to determine a MetS 
latent composite score using baseline data of vascular risk factors. We examined the changes 
of two Alzheimer’s disease (AD) biomarkers, namely [ 18 F]fluorodeoxyglucose (FDG)-positron 
emission tomography (PET) regions of interest and medial temporal lobe volume over 5 years. 
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A cerebrovascular aging index, cerebral white matter (cWM) volume, was examined as a com-
parison.  Results: The vascular risk was similar in all groups. Applying generalized estimating 
equation modeling, all brain-aging indices declined significantly over time. Higher MetS 
scores were associated with a faster decline of cWM in the CN and maMCI groups but with a 
slower decrement of regional glucose metabolism in FDG-PET in the saMCI and maMCI 
groups.  Conclusion: At the very early stage of cognitive decline, the vascular burden such as 
MetS may be in parallel with or independent of AD pathology in contributing to cognitive 
impairment in terms of accelerating the disclosure of AD pathology.  © 2014 S. Karger AG, Basel 
 Introduction 
 Over 40 million Americans aged 60 years or older have one or more risk factors for 
vascular disease, such as obesity, hypertension, and diabetes mellitus  [1] . These risk factors 
contribute to the cognitive decline and development of Alzheimer’s disease (AD)  [2] . Cardio-
vascular risk factors are associated with both brain AD pathology (e.g., decreased cortical 
thickness in the hippocampus and accumulated β-amyloid deposition in the cerebral cortex) 
and vascular pathology (e.g., reduced white matter integrity) in subjects across a range of 
cognitive performance  [3–5] . These relationships may be related to the dysregulation of the 
cerebral blood flow, blood-brain barrier exchange, immune surveillance, trophic support, and 
hemostatic balance, which ultimately leads to cerebral hypoperfusion, gray matter atrophy, 
and white matter damage  [6] . When vascular risk and AD neuropathology co-occur, β-amyloid 
plaques may accumulate in the cerebral vessels and disrupt the vascular integrity, which in 
turn impair the clearance of β-amyloid and synergistically accelerate brain damage and 
cognitive decline  [6] .
 Coexisting cardiovascular risk factors appear to confer greater risks for cognitive decline 
 [7] in addition to AD pathology in aging; however, the relationship between vascular injury 
and AD pathology remains unclear. A recent cross-sectional study with a mixed sample of 
cognitively normal (CN) and moderately demented elderly subjects suggested an association 
between a higher vascular burden indexed by the Framingham Cardiovascular Risk Profile 
(FCRP) score and a lower cerebral glucose metabolism restricted to the frontal lobe  [8] . In 
our previous study, higher FCRP scores did not predict greater AD-like pathological 
progression over time in CN subjects, subjects with amnestic mild cognitive impairment 
(aMCI) or early AD  [9] . However, whether the summary scores for predicting cardiovascular 
events is also applicable or sensitive enough to capture AD-like pathology in aging awaits 
further validation.
 Metabolic syndrome (MetS) is a clinical syndrome representing a common combination 
of several vascular risk factors [obesity, hyperglycemia, high lipid profile, and high blood 
pressure (BP)]. A growing body of literature suggests that MetS contributes to cognitive 
decline and predicts AD prognosis  [10] . The present study examined the relationships 
between MetS and longitudinal changes of two brain-aging indices that reflect early AD 
pathology, [ 18 F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) in five meta-
regions (left/right angular gyrus, left/right temporal gyrus, and bilateral posterior cingulated 
gyrus) and hippocampal volume in CN subjects (normal aging), single-domain aMCI (saMCI) 
and multiple-domain aMCI (maMCI)  [11] . As a comparison, we also examined the effect of 
MetS on cerebral white matter (cWM) volume, which is often indicative of cerebrovascular 
health. We conducted a confirmatory factor analysis (CFA) to determine whether a single 
latent MetS factor can summarize the pathomechanism across multiple vascular risk factors 
 [12] , as a way to quantify the severity of MetS.
186Dement Geriatr Cogn Disord Extra 2014;4:184–194
 DOI: 10.1159/000363285 
E X T R A
 Lin et al.: Longitudinal Effects of Metabolic Syndrome on Alzheimer and Vascular 
Related Brain Pathology 
www.karger.com/dee
© 2014 S. Karger AG, Basel
 Methods 
 Study Population 
 Data used in the preparation of this article were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The primary goal of ADNI has 
been to test whether serial MRI, PET, other biological markers, and clinical and neuropsycho-
logical assessment can be combined to measure the progression of MCI and early AD. The 
principal investigator of this initiative is Michael W. Weiner, MD. ADNI is the result of the 
efforts of many co-investigators from a broad range of academic institutions and private 
corporations, and subjects have been recruited from over 50 sites across the USA and Canada. 
The initial goal of ADNI was to recruit 800 subjects but ADNI has been followed by ADNI-GO 
and ADNI-2. To date, these three protocols have recruited over 1,500 adults aged 55–90 years 
to participate in the research, consisting of CN elderly individuals, subjects with early or late 
MCI, and subjects with early AD. Subjects originally recruited for ADNI-1 and ADNI-GO had 
the option to be followed in ADNI-2. The study procedures were approved by the institutional 
review boards of all participating institutions. Written informed consent was obtained from 
all research participants or their representatives. For up-to-date information, see www.adni-
info.org.
 Other inclusion criteria included having a minimum of 6 years of education, being fluent 
in Spanish or English, and having an informant available for participant functional evaluation. 
Individuals were excluded from the study if they had a Hachinski Ischemic Scale score of 4 or 
greater and used certain psychoactive medications.
 Participants and Timeline 
 The present study used data as of July 2013 from ADNI. We included 739 ADNI partici-
pants who had information on vascular risk factors for developing MetS composite scores. 
Nearly all participants had baseline MRI scans but not necessarily for PET scans and cerebro-
spinal fluid studies, and their length of follow-up varied. The number of participants available 
for an imaging study or neuropsychological assessment at baseline, 6, 12, 24, 36, 48, and 60 
months are presented in the online supplementary Appendix table 1 (for all online suppl. 
material, see www.karger.com/doi/10.1159/000363285). In the present study, we further 
categorized the MCI group from the ADNI dataset to the saMCI and maMCI group based on 
whether the participant had executive deficits (online suppl. Appendix table 2).
 MetS Composite Score 
 Six vascular risk factors including body mass index (BMI), glucose, triglyceride, total 
cholesterol, and systolic and diastolic BP at baseline were collected for developing MetS 
composite scores. Glucose and triglyceride levels were not obtained from fasting blood 
samples, BMI but not waist circumference was available, and the total cholesterol level instead 
of high-density lipoprotein cholesterol was available. In the present study, instead of using 
cutoff scores suggested by the National Cholesterol Education Program Adult Treatment 
Panel III guidelines  [13] , we used CFA to develop the composite scores to better quantify MetS 
(see description in the data analysis section). This method has been used in a previous MetS 
study  [12] .
 Cognition Index 
 Two composite scores for memory and executive function (EF) were developed using 
factor analyses  [14, 15] . The memory composite score was developed based on the following 
tests: the memory items from the Mini-Mental State Examination and Alzheimer’s Disease 
Assessment Scale  − Cognitive Subscale, the Rey Auditory Verbal Learning Test immediate 
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and delayed scores, and the Logical Memory immediate and delayed scores. The EF composite 
score was developed based on the Digit Symbol Substitution test, the Wechsler Memory Scale-
Revised Digit Span test, the Trail Making Test A and B, category fluency tests (animals and 
vegetables), and the Clock Drawing Test.
 Demographic and Health Variables 
 All following data were obtained at baseline: age, sex, education, APOE4 carrier defined 
as having at least one APOE4 allele (by analyzing blood sample at the National Cell Repos-
itory for AD), and presence of cerebral infarction defined as having at least one infarct 
(using a method developed at the University of California at Davis). Aβ 42 and phosphory-
lated tau (p-tau) in cerebrospinal fluid aliquots were measured using the multiplex xMAP 
Luminex platform (Luminex Corp., Austin, Tex., USA) with immunoassay kit-based reagents 
(INNO-BIA AlzBio3; Innogenetics, Ghent, Belgium). An Aβ 42 /p-tau ratio was used as the ‘AD 
signature’ for which lower Aβ 42 /p-tau ratios indicated an increased burden of AD pathology 
 [16] .
 Neuroimaging Methods 
 Two types of imaging methods were included, namely FDG-PET and structural MRI. The 
data acquisition protocols for each imaging modality are detailed on the UCLA laboratory of 
Neuroimaging website (http://www.loni.ucla.edu/ADNI/Data/ADNI_Data.shtml).
 FDG-PET 
 Methods for PET analysis have been described previously  [11] . Briefly, PET images were 
obtained 30–60 min after injection. Functional volumes were averaged, co-registered to 
themselves, transformed to a common space, intensity-normalized, and smoothed with an 
8-mm FWHM Gaussian kernel. The cerebellar vermis, as defined by the MNI atlas, was used 
to normalize the intensity of all PET volumes. Predefined meta-regions typically showing 
altered glucose metabolism within AD patients were first developed for each participant  [11] , 
including the left/right angular gyrus, left/right temporal gyrus, and bilateral posterior cingu-
lated gyrus. A composite score of FDG-PET was then developed by averaging the five meta-
regions.
 Structural MRI 
 MRI acquisition and preprocessing have been described in details previously  [17] . Briefly, 
high-resolution T1 structural images were obtained from all participants on either a 1.5T GE 
scanner (Waukesha, Wisc., USA) or a 1.5T Siemens Medical Solutions MRI (Erlangen, Germany) 
in adherence with the standardized ADNI protocol. To control for cross-site variation, ADNI 
has implemented standardized MRI protocols and acquisition parameters, system-specific 
corrections for gradient nonlinearity and intensity nonuniformity, and phantom-based moni-
toring of imaging instruments. Additional preprocessing and quality control procedures 
included gradient warping, scaling, B1 correction, and N3 inhomogeneity correction on all 
T1-weighted images as performed by the Mayo Clinic.
 Cross-sectional image processing was performed using FreeSurfer version 5.1. Each scan 
is segmented according to an atlas defined by FreeSurfer. This allows for group comparisons 
at a single time point  [18] . Images that did not pass a thorough visual quality control were 
excluded from the analysis. Variables included in the analyses were cWM volume (left and 
right hemispheres) and hippocampus volume. Time-dependent total intracranial volume was 
controlled in all models with structural MRI outcomes.
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 Statistical Analyses 
 CFA was conducted using Mplus 7.0 to determine the structure of MetS. Model fit indices 
included a root mean squared error of approximation of  ≤ 0.06, a standardized root mean 
square residual of  ≤ 0.08, and a comparative fit index of  ≥ 0.90. We followed the model 
developed in a previous CFA study on MetS, taking BMI as the reference and correlating 
triglyceride with the total cholesterol  [12] . We also correlated systolic with diastolic BP. A 
composite score of MetS generated from the CFA was used for subsequent analyses. Given the 
similarity of individual vascular risk factors by diagnostic group ( table 1 ), we only conducted 
a single CFA using the entire sample.
 Other analyses were conducted using SPSS 19.0. A comparison of demographic and 
health variables by diagnostic group was performed using analysis of variance (ANOVA) for 
continuous variables and the χ 2 test for categorical variables, with Bonferroni as post hoc 
analysis.
 We examined the relationships between MetS and changes of each brain-aging index and 
cognitive index over time within each group by a series of generalized estimating equations 
with AR (1) working correlation matrix. All brain-aging indices were normally distributed in 
each diagnostic group. The linear model therefore chosen was  y = β 0 +  β 1 cov 1 …  β n cov  n  +
 β (n + 1) time +  β (n + 2) MetS  +  β ( n  + 3) time × MetS +  Ɛ  (cov 1 to cov n = potential covariates;  β (n + 1) 
= changes of the brain-aging index over time;  β (n + 2) = the influence of MetS on the baseline 
level of the brain-aging index;  β (n + 3) = the influence of MetS on the rate of changes of the 
brain-aging index over time;  Ɛ = the error term). The p value for statistical significance was 
set at 0.05.
 Table 1.  Baseline sample characteristics
Total sample 
(n = 739)
Comparison of three diagnostic groups
CN g roup 
(n = 226)
saMCI group 
(n = 275)
maMCI group 
(n = 238)
ANOVA or 
χ2 test
Age, years 74.51 (7.02) 75.86 (5.00)a 72.35 (7.87)b 75.78 (7.01)a 22.32**
Education, years 15.76 (2.95) 16.02 (2.88)a 16.33 (2.55)a 14.86 (3.23)b 17.86**
APOE4 carrier, n (%) 316 (42.9%) 60 (26.5%)a 130 (47.4%)b 126 (53.2%)b 37.18**
Male gender, n (%) 433 (58.5%) 117 (51.8%)a 164 (59.6%)a, b 152 (63.9%)b 7.19*
Presence of cerebral infarction, n (%) 61 (8.2%) 19 (8.4%) 20 (7.4%) 22 (9.2%) 0.59
Aβ42/p-tau ratio 9.59 (6.85) 10.63 (5.45)a 10.67 (7.61)a 7.38 (6.39)b 11.01**
BMI 26.67 (4.46) 26.74 (4.37) 26.75 (4.59) 26.51 (4.42) 0.23
Glucose‡ 4.60 (0.19) 4.61 (0.18) 4.60 (0.19) 4.59 (0.19) 0.21
Triglyceride‡ 4.84 (0.51) 4.83 (0.52) 4.88 (0.50) 4.80 (0.52) 1.70
Total cholesterol 195.50 (41.32) 192.81 (40.02) 199.49 (41.69) 193.40 (41.93) 2.01
Systolic BP 134.65 (17.28) 134.43 (16.81) 133.55 (16.51) 136.15 (18.51) 1.48
Diastolic BP 74.84 (9.66) 74.63 (10.15) 74.88 (9.66) 75.00 (9.21) 0.09
MetS composite score 0.0002 (0.90) 0.01 (0.91) 0.03 (0.94)  – 0.04 (0.83) 0.34
EF 0.27 (0.81) 0.70 (0.67)a 0.66 (0.48)a  – 0.59 (0.81)b 426.46**
Memory 0.35 (0.35) 0.98 (0.53)a 0.31 (0.60)b  – 0.21 (0.52)c 436.46**
FDG-PET 6.24 (0.67) 6.42 (0.62)a 6.39 (0.61)a 5.89 (0.66)b 29.81**
Hippocampus, cm3 6.63 (1.10) 7.23 (0.91)a 6.87 (1.17)b 6.38 (1.03)c 32.57**
Left-hemisphere cWM, cm3 213.39 (30.40) 215.46  (29.58) 214.55 (31.28) 209.83 (30.38) 1.76
Right-hemisphere cWM, cm3 216.21 (30.03) 217.17 (29.06) 217.79 (31.86) 213.57 (29.37) 0.99
 Unless specifically indicated, all data are represented as mean (SD). ‡ log-transformed; * p < 0.05; ** p < 0.001. Each superscript 
letter denotes a subset of categories whose column proportions do not differ significantly from each other.
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 Results 
 CFA Analysis for the MetS Composite Score 
 CFA was conducted with and without correlations between total cholesterol and triglyc-
eride as well as between systolic and diastolic BP. The best model fit is presented in  figure 1 . 
Model fit indices (root mean squared error of approximation = 0.06, standardized root mean 
square residual = 0.04, and comparative fit index = 0.93) indicated a good model fit. All signif-
icant factors were included in the development of the MetS composite score; diastolic BP was 
excluded due to its insignificant correlation with the latent variable.
 Baseline Sample Characteristics 
 The saMCI group was significantly younger than the other two groups. The maMCI group 
had a significantly lower education, and the CN group had fewer APOE4 carriers. The maMCI 
group had a lower Aβ 42 /p-tau ratio, lower mean EF composite scores, and lower levels of 
glucose metabolism (FDG-PET) than the other two groups, while three groups significantly 
differed in their memory scores and hippocampus volumes.
 When examining the correlation between Aβ 42 /p-tau ratio and MetS within each group, 
lower Aβ 42 /p-tau ratios were significantly associated with lower MetS scores in the saMCI 
group (r = 0.24, p = 0.002, n = 168), approaching significance in the maMCI group (r = 0.16,
p = 0.067, n = 131) but remaining nonsignificant in the CN group (r = 0.04, p = 0.65, n = 109).
 Effect of MetS on Brain-Aging and Cognition Indices over Time 
 Table 2 shows the association between MetS, brain-aging and cognition indices over time 
within each group separately. All brain-aging indices as well as memory declined significantly 
over time in each group; EF significantly declined over time in the saMCI and maMCI groups 
but not in the CN group ( β (n + 1) terms). Higher MetS was associated with a higher hippo-
campus and left hemisphere cWM volume at baseline in the maMCI group but not associated 
with any other brain-aging or cognition indices at baseline in the other groups ( β (n + 2) terms). 
Higher MetS was significantly associated with a faster decline of the left hemisphere cWM 
volume in the CN and maMCI groups and with a slower decline of FDG-PET in the saMCI and 
maMCI groups. MetS was not associated with rates of change in the hippocampal volume, 
right hemisphere cWM, or cognition indices ( β (n + 3) terms).
BMI 
Glucose
Total
cholesterol
Systolic BP
Diastolic
BP
MetS
Triglyceride
0.46 (0.08)***0.32 (0.06)***
0.48 (0.09)***
–0.19 (0.07)*
0.11 (0
.06)*
0.09
 (0.0
7)
Not
 incl
ude
d in
 the
 fina
l mo
del
 Fig. 1. Developing the MetS com-
posite score using CFA. Glucose 
and triglyceride were log-trans-
formed. All vascular risk factors 
were standardized. BMI was tak-
en as a reference. Equation for de-
veloping MetS composite score: 
0.46 BMI + 0.32 glucose + 0.48 tri-
glyceride – 0.19 total cholesterol +
0.11 systolic BP.  * p < 0.05;  * * * p < 
0.001. 
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 Discussion 
 In the present study on three nondementia scenarios (CN, saMCI, and maMCI), we 
examined brain-aging indices including AD-like (hypometabolism in angular, temporal, and 
posterior cingulated gyri as well as hippocampal atrophy) and vascular pathological (reduced 
cWM volume) changes. All brain-aging indices declined significantly over time across all 
groups. The MCI groups also had a significant cognitive decline over time. The influence of 
MetS on the change in the brain-aging indices over time differed across the groups, particu-
larly in the cerebrovascular aspect that higher MetS scores accelerated the decline of left 
hemisphere cWM in the maMCI and CN groups. We found no evidence, at least in the early 
stage of cognitive aging, to support the hypothesis that MetS would contribute the AD 
pathology. The association between greater MetS and a slower decline in FDG in the MCI 
groups should be cautiously interpreted given the potential inverse correlations found 
between AD pathology (Aβ 42 /p-tau ratio) and MetS levels.
 The study has several unique features. First, we developed a MetS composite score to 
reflect relevant vascular burden. It provided a more direct and quantitative way to capture 
the severity of MetS than simply using the presence or absence of MetS diagnosis. Of note, 
given the lack of data on high-density lipoprotein, we used total cholesterol when developing 
the latent MetS score. Previous studies have failed to find a consistent effect of total choles-
terol on brain pathology as opposed to other individual vascular risk factors, suggesting that 
total cholesterol is a complex if its components are not singled out. Second, we compared 
three nondementia elderly groups, which may either present a normal aging process, AD 
pathology, or AD/vascular pathology. Such a comparison provides the possibility to explicate 
the influence of MetS on different mechanisms involved in the very early stage of cognitive 
decline. Third, we controlled multiple factors including the genetic (APOE4 allele) back-
ground and brain size (intracranial volume) important for confounding the MetS effects but 
rarely available in longitudinal studies.
 Although accumulated literature supports the association between individual vascular 
risk factors and cerebrovascular pathology  [19] , there is a lack of evidence regarding the 
longitudinal effects of MetS on brain aging within the context of AD pathology. In the present 
study, MetS accelerated the loss of left-, but not right-hemisphere cWM in cognitively healthy 
elderly adults and those with maMCI. MetS seemed to favorably affect the left hemisphere, 
and this finding was in line with two previous studies regarding the association between 
Framingham’s vascular index and cerebral glucose hypometabolism  [8] as well as the asso-
ciation between hypertension and a lower cerebral blood flow. Both studies preferred the left 
hemisphere among cognitively healthy elderly adults  [20] . The left hemisphere was found to 
be more sensitive to BP changes  [21] , and therefore, MetS may have a greater impact on left-
hemisphere cWM. MetS may alter the neurovascular unit, leading to the damage of cWM  [6] . 
Higher MetS was associated with more prevalent and severe silent brain infarction  [22] , 
lower fractional anisotropy of diffusion tensor imaging (DTI)  [23] , and higher WM hyperin-
tensity  [24] . Previous studies also found that the maMCI group has significantly more WM 
damage than the saMCI group  [25] . When AD pathology outweighs cerebrovascular pathology, 
as often seen in the saMCI group, AD pathology may dominate the degenerative process, 
making effects of MetS on saMCI less conspicuous.
 AD-like pathological changes including synaptic dysfunction and neuronal death were 
reflected by regional glucose hypometabolism and hippocampal atrophy, respectively, in our 
study. Higher MetS was associated with a slower decline in AD-like pathological progression 
over time in the MCI groups. We also found that higher Aβ 42 /p-tau ratios, indicating lower AD 
pathology, were associated with higher MetS levels. Similar associations were found in 
previous studies. For example, a higher BMI was associated with lower levels of neuritic 
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plaques, diffuse plaques, and neurofibrillary tangles in the brain  [26] . Having diabetes mellitus 
was associated with less severe β-amyloid accumulation in the hippocampus  [27] . These 
findings may at first sight contradict to our concept that increased vascular burden is asso-
ciated with higher risks of AD. One possibility is that MCI participants were enrolled based on 
cognitive function, and at a given level of cognitive impairment, subjects with an increased 
MetS burden may have less severe AD pathology or less AD-like pathological progression. Such 
proposition is based on the evidence that microvascular disease may decrease the threshold 
for AD pathology or amplify the consequence of neurodegenerative pathology to produce 
clinical symptoms such as memory or executive deficits  [19, 28] . Higher MetS may not directly 
protect the brain from AD pathology but rather accelerate the disclosure of AD pathology.
 There are several limitations in our study. First, the vascular burden in these cohorts was 
relatively low (Hachinski <4), limiting the generalizability of our findings to subjects with 
mild degrees of MetS. Next, we used T1-weighted MRI-based cWM volume to reflect WM 
integrity, and this measurement may be less sensitive than DTI. We expect to have more DTI 
data from ADNI-GO and ADNI-2 to further validate our current findings. Third, MetS composite 
scores were determined at baseline, but the status or severity of MetS may fluctuate over time 
as well, especially for those who had concurrent medical control. Collecting information on 
time-varying vascular risks is warranted in future investigation. Finally, less than 10% of the 
participants had 5 years’ follow-up. In our relatively healthy sample, the influence of MetS on 
AD pathology may not be detectable within this observation period.
 The neurovascular hypothesis was proposed within the context of AD such that the inter-
action occurs later in the disease course with more β-amyloid deposition or neurofibrillary 
tangle burden  [6] , while at the very early stage of cognitive decline, the vascular burden such 
as MetS may be in parallel with or independent of AD pathology in contributing to cognitive 
impairment in terms of accelerating the disclosure of AD pathology.
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